BR9804826A - Proteìna de fusão antigênica portando epìtopos galoc 1,3 gal - Google Patents

Proteìna de fusão antigênica portando epìtopos galoc 1,3 gal

Info

Publication number
BR9804826A
BR9804826A BR9804826-0A BR9804826A BR9804826A BR 9804826 A BR9804826 A BR 9804826A BR 9804826 A BR9804826 A BR 9804826A BR 9804826 A BR9804826 A BR 9804826A
Authority
BR
Brazil
Prior art keywords
polypeptide
galoc
gal
epitopes
fusion protein
Prior art date
Application number
BR9804826-0A
Other languages
English (en)
Inventor
Jan Holgersson
Jining Liu
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Publication of BR9804826A publication Critical patent/BR9804826A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"PROTEìNA DE FUSãO ANTIGêNICA PORTANDO EPìTOPOS GAL<244>1, 3GAL". A proteína de fusão, de acordo com a invenção pode ser compreendida de uma parte de mucina altamente glicosilada, que media a ligação às selectinas, tal como, PSGL-1 e uma parte, que exibe propriedades de imunoglobulina, tal como a parte Fc do IgG. A proteína de fusão, de acordo com a invenção é preferivelmente usada como um absorvedor para impedir uma rejeição hiperaguda de um xenotransplante, tal como, tecido ou órgão de porco transplantado para um paciente humano. Além disto, a invenção refere-se a um processo para prevenção de reação de rejeição hiperaguda em um paciente que deve receber um xenotransplante.
BR9804826-0A 1997-03-26 1998-03-26 Proteìna de fusão antigênica portando epìtopos galoc 1,3 gal BR9804826A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9701127A SE9701127D0 (sv) 1997-03-26 1997-03-26 Antigenic fusionprotein carrying GALal, 3GAL epitopes
PCT/SE1998/000555 WO1998042750A1 (en) 1997-03-26 1998-03-26 ANTIGENIC FUSIONPROTEIN CARRYING GALα1,3GAL EPITOPES

Publications (1)

Publication Number Publication Date
BR9804826A true BR9804826A (pt) 2000-01-25

Family

ID=20406335

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9804826-0A BR9804826A (pt) 1997-03-26 1998-03-26 Proteìna de fusão antigênica portando epìtopos galoc 1,3 gal

Country Status (12)

Country Link
US (3) US6943239B2 (pt)
EP (2) EP0923606B1 (pt)
JP (1) JP4099239B2 (pt)
AT (1) ATE315047T1 (pt)
AU (1) AU751760B2 (pt)
BR (1) BR9804826A (pt)
CA (1) CA2255765A1 (pt)
DE (1) DE69833106T2 (pt)
DK (1) DK0923606T3 (pt)
ES (1) ES2258297T3 (pt)
SE (1) SE9701127D0 (pt)
WO (1) WO1998042750A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010201A2 (en) * 2001-07-20 2003-02-06 Absorber, Ab Blood group antigen fusion polypeptides and methods of use thereof
AU2003233008B2 (en) * 2002-04-22 2008-04-24 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
CA2483473A1 (en) * 2002-04-22 2003-10-30 Absorber, Ab Mucin fusion polypeptide vaccines, compositions and methods of use thereof
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス， インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
AU2003245595A1 (en) * 2002-07-03 2004-01-23 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
JP4648001B2 (ja) * 2002-08-09 2011-03-09 レコファーマ アーベー ムチン−免疫グロブリン融合タンパク質
US20050076759A1 (en) * 2003-10-08 2005-04-14 Brian Westfall Linear saw with stab-cut bevel capability
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
WO2005047320A2 (en) * 2003-11-12 2005-05-26 Wisconsin Alumni Research Foundation Equine p-selection glycoprotein ligand-1 and uses thereof
ATE383367T1 (de) * 2003-11-19 2008-01-15 Glycomimetics Inc Spezifischer antagonist sowohl für e- als auch p- selektine
US20050187171A1 (en) * 2003-11-19 2005-08-25 Glycomimetics, Inc. Glycomimetic antagonists for both E-and P-selectins
EP1782838A4 (en) * 2004-06-23 2007-08-01 Japan Science & Tech Agency INHIBITION OF INFILTRATION AND AGENT TAKING CELLS
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
US20090036386A1 (en) * 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
CA2618638C (en) * 2005-08-09 2014-03-11 Glycomimetics, Inc. Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas
SI2264043T1 (en) 2005-09-02 2018-01-31 Glycomimetics, Inc. HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
EP2264060B1 (en) * 2006-01-26 2014-04-23 Recopharma AB Compositions and methods for inhibiting viral adhesion
US20070178447A1 (en) * 2006-01-31 2007-08-02 Bethyl Laboratories, Inc. Method for decreasing interference in results of immunochemical methods
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
WO2008060378A2 (en) 2006-10-12 2008-05-22 Glycomimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
EP2457573A1 (en) * 2007-02-09 2012-05-30 GlycoMimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and N-Acetyl hexosamines
US8039442B2 (en) * 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2009126556A1 (en) * 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2009152245A1 (en) * 2008-06-13 2009-12-17 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
JP5726171B2 (ja) 2009-05-01 2015-05-27 グリコミメティックス インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US20120165272A1 (en) * 2010-12-21 2012-06-28 Recopharma Ab Tear Substitutes
CA2858099C (en) 2011-12-22 2020-12-15 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
WO2014089269A1 (en) 2012-12-07 2014-06-12 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
WO2016089872A1 (en) 2014-12-03 2016-06-09 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
CA3009836A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
CN111867601A (zh) 2018-03-05 2020-10-30 糖模拟物有限公司 用于治疗急性髓系白血病及相关病症的方法
US20210260250A1 (en) * 2018-06-12 2021-08-26 Rush University Medical Center Methods for Enhanced Endothelialization of Implanted Material
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3722375B2 (ja) * 1991-06-27 2005-11-30 ブリストル−マイヤーズ スクイブ カンパニー Ｃｔｌａ４レセプター、それを含有する融合タンパク質およびそれらの使用
CA2147623C (en) * 1992-10-23 2005-05-03 Glenn R. Larsen Novel p-selectin ligand protein
WO1994021799A1 (en) 1993-03-16 1994-09-29 Austin Research Institute USE OF PORCINE GAL α(1,3) GALACTOSYL TRANSFERASE IN XENOGRAFT THERAPIES
GB9517758D0 (en) * 1995-08-31 1995-11-01 Imutran Ltd Compositions and their uses

Also Published As

Publication number Publication date
SE9701127D0 (sv) 1997-03-26
EP1700868A3 (en) 2007-12-12
US20050255099A1 (en) 2005-11-17
DE69833106T2 (de) 2006-08-31
WO1998042750A1 (en) 1998-10-01
DE69833106D1 (de) 2006-03-30
AU751760B2 (en) 2002-08-29
JP4099239B2 (ja) 2008-06-11
CA2255765A1 (en) 1998-10-01
US20090286963A1 (en) 2009-11-19
US6943239B2 (en) 2005-09-13
ES2258297T3 (es) 2006-08-16
EP1700868A2 (en) 2006-09-13
AU6755198A (en) 1998-10-20
DK0923606T3 (da) 2006-05-22
EP0923606B1 (en) 2006-01-04
EP0923606A1 (en) 1999-06-23
ATE315047T1 (de) 2006-02-15
US20020028205A1 (en) 2002-03-07
JP2000511782A (ja) 2000-09-12

Similar Documents

Publication Publication Date Title
BR9804826A (pt) Proteìna de fusão antigênica portando epìtopos galoc 1,3 gal
DK0739413T3 (da) Fremgangsmåde til udvælgelse af specifikke bakteriofager
EP0699755A3 (en) Process for obtaining modified immunoglobulins with reduced immunogenicity of the variable domains of a murine antibody, compositions containing them
ES2087323T3 (es) Metodo para producir peptidos exentos de cisteina.
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
KR960022559A (ko) 슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
ATE230020T1 (de) Katalytische antikörperkomponente
ATE159532T1 (de) Verfahren zur reinigung von igg-monoklonalen antikörpern
ZA874558B (en) Monoclonal antibodies to unreduced,nonenzymatically-glycated proteins
KR880700823A (ko) 사이토메갈로 바이러스에 대한 사람.모노클로날 항체와 그 제조방법
AU2707992A (en) Monoclonal antibodies to hepatitis c virus
DE3688100D1 (de) Polyvalentes hyperimmunglobulin-praeparat.
AU2002363465A1 (en) Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
DE69630008D1 (de) Treponema palladium Fusions-Antigen, Nachweis für Anti-treponema palladium Antikörpern mit diesen Fusions-Antigenen
ATE207935T1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
AU5398898A (en) Recombinant fusion proteins of the porcine reproductive and respiratory syndrome virus (PRRSV) and its use in diagnosis
ATE103973T1 (de) Gamma-atriales, natriuretisches polypeptid erkennende monoklonale antikoerper, solche antikoerper produzierende hybridome und deren herstellung und verwendung.
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ABSORBER AB (SE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO, ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.